WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

LIPOSOMAL FORMULATION AND EVALUATION OF ANTICANCER DRUG GEMCITABINE

K. Jyothi*, A. Anil Kumar and Srinivasa Rao

ABSTRACT

Gemcitabine is a potent anticancer drug approved for the treatment of pancreatic, non-small-cell lung, breast, and ovarian cancers. Gemcitabine is a highly reactive molecule and binds extensively to plasma and tissue proteins leading to a fast inactivation of a large part of the administered dose. Thus, the clinical use of Gemcitabine faces two major problems, serious dose-limiting toxicities and rapid inactivation of the drug in the circulation. Both problems could possibly be prevented by shielding of the drug from the extracellular environment by means of a lipid coating. In the present investigation Gemcitabine loaded long circulating liposomes were prepared by thin film hydration method. By using different concentrations of PEGylated phospholipids, from the preliminary in vivo work, it was observed that stealth liposome’s formulation was better than free Gemcitabine. Stealth liposome’s formulation decreased the volume of solid tumor as well as ascites volume, decreased average body weight and increased the life span. In vivo pharmacokinetic studies were carried out in lymphoma bearing mice and the drug was detected in plasma even after 24 hours. This reveals that the stealth liposome’s formulation had improved stability in the biological fluids. Tissue distribution studies done in the drug loaded long circulating liposome’s showed preferential drug targeting to liver followed by spleen, lungs, and kidneys. Higher concentration of drug was targeted to the organs after administering the dose in the form of long circulating liposomes except in the heart. Drug levels in the heart are closely related to the inherent cardiac toxicity of Gemcitabine. Therefore using liposomal Gemcitabine formulation could reduce the cardiac toxicity of Gemcitabine.

Keywords: Gemcitabine, Liposomes, PEGylated phospholipids, Cancer.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More